Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells 875 Shares of Stock
Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $20.00, for a total transaction of $17,500.00. Following the completion of the transaction, the insider now directly owns 4,697 shares in the company, valued at approximately $93,940. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
David Y. Liu also recently made the following trade(s):
- On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00.
Protagonist Therapeutics Inc (NASDAQ:PTGX) traded up $0.08 during trading on Wednesday, reaching $19.46. 139,716 shares of the company traded hands, compared to its average volume of 102,872. Protagonist Therapeutics Inc has a 12-month low of $8.00 and a 12-month high of $21.68. The stock has a market cap of $397.55 and a P/E ratio of -7.00.
A number of institutional investors have recently added to or reduced their stakes in PTGX. Rhumbline Advisers purchased a new stake in Protagonist Therapeutics during the 2nd quarter worth $114,000. Bank of Montreal Can increased its stake in Protagonist Therapeutics by 1,086.0% during the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after buying an additional 5,430 shares during the period. Wells Fargo & Company MN increased its stake in Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after buying an additional 3,617 shares during the period. Teachers Advisors LLC increased its stake in Protagonist Therapeutics by 71.4% during the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after buying an additional 6,757 shares during the period. Finally, California State Teachers Retirement System increased its stake in Protagonist Therapeutics by 8.5% during the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after buying an additional 1,300 shares during the period. 39.68% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on PTGX shares. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 4th. BidaskClub raised shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Finally, BMO Capital Markets raised their target price on shares of Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.67.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells 875 Shares of Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/17/insider-selling-protagonist-therapeutics-inc-ptgx-insider-sells-875-shares-of-stock.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Stock Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related stocks with our FREE daily email newsletter.